MarketPulse

Phase 1 trial

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Telix Pharmaceuticals Limited

Telix Hits Dosing Milestone in Glioblastoma Study as Radiopharmaceutical Therapy Advances

Telix Pharmaceuticals completes enrollment in IPAX-2 glioblastoma study, reaching maximum 10GBq dose with no toxicities observed. Phase 3 trial advancement marks first radiopharmaceutical therapy for this indication.
TLXPhase 3 trialorphan drug designation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

ArriVent Advances Dual-Target Cancer Drug as FDA Clears IND for Novel ADC

ArriVent BioPharma wins FDA clearance for ARR-002, a first-in-class dual-target ADC targeting ovarian and endometrial cancers, with Phase 1 trials expected in H2 2026.
AVBPantibody-drug conjugateovarian cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Na

LBL-047 Advances to Clinical Testing for Autoimmune Diseases as Dianthus Raises $719M

Nanjing Leads Biolabs and Dianthus Therapeutics advance LBL-047, a bifunctional fusion protein, into Phase 1 trials for three autoimmune conditions with $719M in funding.
DNTHclinical developmentautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Beyond Air, Inc.

Beyond Cancer's UNO Therapy Shows Durable Survival Gains in Early-Stage Cancer Trial

Beyond Cancer presented Phase 1 UNO trial data with six of ten patients alive 22-40 months post-treatment and secured U.S. patent for gas delivery technology.
XAIRbreast cancercancer treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Pliant Therapeutics' PLN-101095 Shows Promise in Hard-to-Treat Cancer Patients

Pliant Therapeutics presented Phase 1 data for PLN-101095 showing 89% average tumor reduction in ICI-refractory cancer patients, with Phase 1b expansion underway.
PLRXimmunotherapyPhase 1 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Mestag's MST-0312 Advances to AACR Stage Ahead of Mid-2026 Clinical Launch

Mestag Therapeutics' FAP-targeted bispecific antibody MST-0312 selected for late-breaking AACR presentation in April 2026, with Phase 1 trials expected to begin mid-year.
JNJMRKsolid tumorsbispecific antibody
BenzingaBenzinga··Na

Novartis Acquires Allergy Biotech Excellergy for Up to $2B in Transformative Deal

Novartis to acquire allergy biotech Excellergy for up to $2 billion, gaining first-in-class ECRI technology and lead candidate Exl-111 currently in Phase 1 trials.
NVSacquisitiondrug development